Standard usage and dosage of giritinib (segatan) and recommendations for individualized adjustments

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly used to treat relapsed or refractory acute myeloid leukemia (R/R AML) carrying FLT3 mutations patients. The standard usage is to take it orally once a day, and the recommended dose is 120 mg/day. It is usually taken continuously under the guidance of a doctor until disease progression or intolerable adverse reactions occur. This dose showed optimal efficacy and tolerability in clinical trials.

Individualized adjustments are mainly aimed at adverse reactions or special patient groups. If patients develop moderate to severe liver function abnormalities, the dose may need to be reduced to 80 mg/day or less and liver function indicators should be closely monitored. In addition, patients with renal insufficiency should also be used with caution, and if necessary, adjust the dose or extend the reexamination interval to reduce the risk of toxicity caused by drug accumulation.

During the treatment process, blood routine, electrolytes, liver and kidney function and electrocardiogram should be monitored regularly, with special attentionQT prolongation and blood picture abnormalities. If severe bone marrow suppression or cardiovascular toxicity occurs, the drug can be temporarily discontinued and the dose can be resumed after the symptoms are relieved, adjusting the dose according to the patient's tolerance. Some patients may need to start at a lower dose initially and then gradually increase to a standard dose to reduce the risk of side effects.

In addition, individualized medication also needs to consider Concomitant medication. Giritinib may interact with potent CYP3A4 inhibitors or inducers, affecting plasma concentrations. When coadministered, the dose of giritinib should be adjusted or plasma levels should be monitored based on the risk of interaction. Through scientific dose adjustment and regular monitoring, the efficacy can be maximized, while the incidence of side effects can be reduced, achieving safe and effective individualized treatment.

Reference materials:https://www.drugs.com/